Table of Contents Author Guidelines Submit a Manuscript
International Journal of Breast Cancer
Volume 2017 (2017), Article ID 1257078, 6 pages
https://doi.org/10.1155/2017/1257078
Research Article

Correlation of Oncotype DX Recurrence Score with Histomorphology and Immunohistochemistry in over 500 Patients

1Department of Pathology, University of Pittsburgh, School of Medicine, S-417 BST, 200 Lothrop Street, Pittsburgh, PA 15261, USA
2Department of Pathology, Hospital of the University of Pennsylvania, University of Pennsylvania, Founders 6, 3400 Spruce St., Philadelphia, PA 19104, USA
3Department of Pathology, Icahn School of Medicine at Mount Sinai, One Gustave L Levy Pl., P.O. Box 1194, New York, NY 10029, USA

Correspondence should be addressed to Shabnam Jaffer

Received 4 August 2016; Accepted 14 December 2016; Published 12 January 2017

Academic Editor: Debra A. Tonetti

Copyright © 2017 Matthew G. Hanna et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Paik, S. Shak, G. Tang et al., “A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer,” New England Journal of Medicine, vol. 351, no. 27, pp. 2817–2826, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. S. M. O'Connor, S. Beriwal, D. J. Dabbs, and R. Bhargava, “Concordance between semiquantitative immunohistochemical assay and oncotype DX RT-PCR assay for estrogen and progesterone receptors,” Applied Immunohistochemistry and Molecular Morphology, vol. 18, no. 3, pp. 268–272, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. K. H. Allison, P. L. Kandalaft, C. M. Sitlani, S. M. Dintzis, and A. M. Gown, “Routine pathologic parameters can predict oncotype DXTM recurrence scores in subsets of ER positive patients: who does not always need testing?” Breast Cancer Research and Treatment, vol. 131, no. 2, pp. 413–424, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Antonio, E. H. Hammond, D. C. Hicks et al., “Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update,” Journal of Clinical Oncology, vol. 31, no. 31, pp. 3997–4013, 2013. View at Publisher · View at Google Scholar
  5. G. Acs, N. N. Esposito, J. Kiluk, L. Loftus, and C. Laronga, “A mitotically active, cellular tumor stroma and/or inflammatory cells associated with tumor cells may contribute to intermediate or high Oncotype DX Recurrence Scores in low-grade invasive breast carcinomas,” Modern Pathology, vol. 25, no. 4, pp. 556–566, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. M. M. Park, J. J. Ebel, W. Zhao, and D. L. Zynger, “ER and PR immunohistochemistry and HER2 FISH versus oncotype DX: implications for breast cancer treatment,” The Breast Journal, vol. 20, no. 1, pp. 37–45, 2014. View at Publisher · View at Google Scholar
  7. J. Cuzick, M. Dowsett, S. Pineda et al., “Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the genomic health recurrence score in early breast cancer,” Journal of Clinical Oncology, vol. 29, no. 32, pp. 4273–4278, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. P. Tang, J. Wang, D. G. Hicks et al., “A lower allred score for progesterone receptor is strongly associated with a higher recurrence score of 21-gene assay in breast cancer,” Cancer Investigation, vol. 28, no. 9, pp. 978–982, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. B. Z. Clark, D. J. Dabbs, K. L. Cooper, and R. Bhargava, “Impact of progesterone receptor semiquantitative immunohistochemical result on oncotype DX recurrence score: a quality assurance study of 1074 cases,” Applied Immunohistochemistry and Molecular Morphology, vol. 21, no. 4, pp. 287–291, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. P. E. Bomeisl, C. L. Thompson, L. N. Harris, and H. L. Gilmore, “Comparison of oncotype DX recurrence score by histologic types of breast carcinoma,” Archives of Pathology and Laboratory Medicine, vol. 139, no. 12, pp. 1546–1549, 2015. View at Publisher · View at Google Scholar · View at Scopus
  11. M. L. Tsai, T. J. Lillemoe, M. J. Finkelstein et al., “Utility of oncotype DX risk assessment in patients with invasive lobular carcinoma,” Clinical Breast Cancer, vol. 16, no. 1, pp. 45–50, 2016. View at Publisher · View at Google Scholar · View at Scopus
  12. N. Conlon, D. S. Ross, J. Howard, J. P. Catalano, M. N. Dickler, and L. K. Tan, “Is there a role for oncotype Dx testing in invasive lobular carcinoma?” Breast Journal, vol. 21, no. 5, pp. 514–519, 2015. View at Publisher · View at Google Scholar · View at Scopus
  13. S. S. Badve, F. L. Baehner, R. P. Gray et al., “Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory,” Journal of Clinical Oncology, vol. 26, no. 15, pp. 2473–2481, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. J. A. Kraus, D. J. Dabbs, S. Beriwal, and R. Bhargava, “Semi-quantitative immunohistochemical assay versus oncotype DX® qRT-PCR assay for estrogen and progesterone receptors: an independent quality assurance study,” Modern Pathology, vol. 25, no. 6, pp. 869–876, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. F. L. Baehner, C. Pomeroy, C. Cherbavaz, and S. Shak, “Biopsy cavities in breast cancer specimens: their impact on quantitative RT-PCR gene expression profiles and recurrence risk assessment,” Modern Pathology, vol. 22, no. 1, pp. 28A–29A, 2009. View at Google Scholar
  16. D. J. Dabbs, M. E. Klein, S. K. Mohsin, R. R. Tubbs, Y. Shuai, and R. Bhargava, “High false-negative rate of HER2 quantitative reverse transcription polymerase chain reaction of the Oncotype DX test: an independent quality assurance study,” Journal of Clinical Oncology, vol. 29, no. 32, pp. 4279–4285, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. J. Auerbach, M. Kim, and S. Fineberg, “Can features evaluated in the routine pathologic assessment of lymph node-negative estrogen receptor-positive stage I or II invasive breast cancer be used to predict the oncotype DX recurrence score?” Archives of Pathology and Laboratory Medicine, vol. 134, no. 11, pp. 1697–1701, 2010. View at Google Scholar · View at Scopus
  18. M. Dowsett, J. Houghton, C. Iden et al., “Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status,” Annals of Oncology, vol. 17, no. 5, pp. 818–826, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. G. Arpino, H. Weiss, A. V. Lee et al., “Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance,” Journal of the National Cancer Institute, vol. 97, no. 17, pp. 1254–1261, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Dowsett, C. Allred, J. Knox et al., “Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the arimidex, tamoxifen, alone or in combination trial,” Journal of Clinical Oncology, vol. 26, no. 7, pp. 1059–1065, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Dowsett, J. Cuzick, C. Wale, T. Howell, J. Houghton, and M. Baum, “Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study,” Journal of Clinical Oncology, vol. 23, no. 30, pp. 7512–7517, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. R. L. Balleine, M. J. Earl, M. L. Greenberg, and C. L. Clarke, “Absence of progesterone receptor associated with secondary breast cancer in postmenopausal women,” British Journal of Cancer, vol. 79, no. 9-10, pp. 1564–1571, 1999. View at Publisher · View at Google Scholar · View at Scopus
  23. Y. W. Moon, S. Park, J. H. Sohn et al., “Clinical significance of progesterone receptor and HER2 status in estrogen receptor-positive, operable breast cancer with adjuvant tamoxifen,” Journal of Cancer Research and Clinical Oncology, vol. 137, no. 7, pp. 1123–1130, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. M. E. Hammond, D. F. Hayes, M. Dowsett et al., “American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer,” Journal of Clinical Oncology, vol. 28, no. 16, pp. 2784–2795, 2010. View at Publisher · View at Google Scholar
  25. M. Dowsett, J. Cuzick, C. Wale et al., “Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study,” Journal of Clinical Oncology, vol. 28, no. 11, pp. 1829–1834, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. K. S. Albain, W. E. Barlow, S. Shak et al., “Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial,” The Lancet Oncology, vol. 11, no. 1, pp. 55–65, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. A. E. Giuliano, D. Hawes, K. V. Ballman et al., “Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer,” Journal of The American Medical Association, vol. 306, no. 4, pp. 385–393, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. M. De Boer, C. H. M. Van Deurzen, J. A. A. M. Van Dijck et al., “Micrometastases or isolated tumor cells and the outcome of breast cancer,” New England Journal of Medicine, vol. 361, no. 7, pp. 653–663, 2009. View at Publisher · View at Google Scholar · View at Scopus